Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clonal persistence of BRAFV600E under MEK inhibition in histiocytosis

Blood (2025) 146 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2025-1495

Published: 2025

Journal Articles

Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies

Refael Meyuchas, Tamar Ziv, Mali Salmon-Divon, Ofer Shpilberg, May Basood, Benjamin Durham, Matthias Papo, Fleur Cohen-Aubart, Omar Abdel-Wahab, Eli Diamond, Julien Haroche, Oshrat Hershkovitz-Rokah

Blood (2025) 146 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2025-1211

Published: 2025

Journal Articles

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

Blood (2025) 146 (Supplement 1): 192.

https://doi.org/10.1182/blood-2025-192

Published: 2025

Journal Articles

Impact of additional genetic variants in the course of erdheim-chester disease and their evolution on treatment: A multicentric longitudinal Study of 445 french patients

Félicien Triboulet, Matthias Papo, Fleur Cohen-Aubart, Francesco Pegoraro, Ahmed Idbaih, Damien Roos Weil, Jean-Francois Emile, Zahir Amoura, Pierre Hirsch, Julien Haroche

Blood (2025) 146 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2025-4770

Published: 2025

Journal Articles

Clinical and molecular predictors of interferon-α response in erdheim-chester disease and myeloproliferative neoplasm.

Jerome Razanamahery, Francesco Pegoraro, Dana Bossert, Matthias Papo, Jean-Francois Emile, Francesco Poeta, Bernard Bonnotte, Louis Terriou, Noemie Gensous, Tanguy Le scornet, Etienne Riviere, Ludwig Aho, Adrien Guilloteau, Marc Maynadié, Zahir Amoura, Fleur Cohen-Aubart, Eli Diamond, Augusto Vaglio, Julien Haroche

Blood (2025) 146 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2025-3802

Published: 2025

Journal Articles

Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Ambroise Le Pogam, Matthias Papo, Pierre Hirsh, Jean-Francois Emile, Pierre Duffau, Jerome Razanamahery, Estibaliz Lazarro, Damiens Roos-Weil, Fleur Cohen-Aubart, Vincent Jachiet, Arsene Mekinian, Olivier Fain, Zahir Amoura, Jerome Hadjadj, Julien Haroche

Blood (2024) 144 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2024-209641

Published: 2024

Journal Articles

Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France

Blood (2023) 142 (24): 2119–2123.

https://doi.org/10.1182/blood.2023021670

Published: 2023

Includes: Supplemental data

Journal Articles

High Prevalence of Vulvar and Hepatic Manifestations in a Series of 18 Histiocytosis with Brafdel Mutations

Matthias Papo, Julien Haroche, Malik Da Silva, Zofia Helias-Rodzewicz, Vsevolod Potapenko, Suzanna Bota, Leguy-Seguin Vanessa, Stéphane Dominique, Marion Campana, Visal Keo, Zahir Amoura, Jean-Francois Emile

Blood (2023) 142 (Supplement 1): 6392.

https://doi.org/10.1182/blood-2023-174667

Published: 2023

Journal Articles

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis

Blood (2017) 130 (8): 1007–1013.

https://doi.org/10.1182/blood-2017-01-761718

Published: 2017

Includes: Supplemental data

Journal Articles

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells

Blood (2017) 130 (2): 176–180.

https://doi.org/10.1182/blood-2016-12-757377

Published: 2017

Includes: Supplemental data

Journal Articles

Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses

Benjamin Heath Durham, MD BS, Akihide Yoshimi, MD PhD, Matthias Papo, Young Rock Chung, MS, Neval Ozkaya, MD, Chezi Ganzel, Ahmet Dogan, David M. Hyman, Christopher Y. Park, MD PhD, Raajit K. Rampal, MD, PhD, Damien Roos Weil, Francois Michel Lemoine, MD PhD, Zahir Amoura, Olivier A. Bernard, PhD, Eli L. Diamond, MD, Jean-François Emile, MD PhD, Julien Haroche, MD PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 951.

https://doi.org/10.1182/blood.V128.22.951.951

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal persistence of BRAFV600E under MEK inhibition in histiocytosis

Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

Impact of additional genetic variants in the course of erdheim-chester disease and their evolution on treatment: A multicentric longitudinal Study of 445 french patients

Clinical and molecular predictors of interferon-α response in erdheim-chester disease and myeloproliferative neoplasm.

Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France

High Prevalence of Vulvar and Hepatic Manifestations in a Series of 18 Histiocytosis with Brafdel Mutations

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells

Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only